Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Conditional Survival Analysis of Metastatic Colorectal Cancer Patients Living ≥24 Months

A Single Institutional Study

Ali, Nadia D., MD*; Donohue, Kristen, MD; Zandieh, Shadi, MD; Chen, Chunxia, MS§; Moore, Dirk, PhD§; Poplin, Elizabeth, MD‡,∥; Shah, Mihir M., MD†,¶; Nosher, John, MD#; Gui, Bin, MS; Jabbour, Salma K., MD**; Spencer, Kristen, MD‡,∥; Carpizo, Darren R., MD, PhD†,¶

American Journal of Clinical Oncology: June 2019 - Volume 42 - Issue 6 - p 512–518
doi: 10.1097/COC.0000000000000535
Original Articles: Gastrointestinal
Buy
SDC

Objectives: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions.

Materials and Methods: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155). Patient tumor and treatment related variables were collected. Overall survival (OS) estimates conditional on surviving >24 months were compared with actuarial survival estimates of a cohort of patients (33,104 resected, 39,382 unresected) from the National Cancer Database (NCDB).

Results: With a median follow-up of 44.2 months, the median OS of resected patients (n=86) was not reached. The median OS of unresected patients was 75.9 months. The conditional survival probabilities of living 1, 2, or 3 years longer after 24 months of survival are 92%, 72%, and 52%, respectively, in unresectable patients and 98%, 92%, and 89% in patients who were resected. The corresponding NCDB 1, 2, and 3 year actuarial survival was 38%, 20%, and 11% for unresected patients and 68%, 46%, and 32% for resected.

Conclusions: These results indicate that CRC patients who survive 24 months with metastatic colorectal cancer have an excellent prognosis and surgery may be appropriate in a subset of patients initially deemed unresectable.

*Department of Medicine, Section of Hematology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

Departments of Medical Oncology

Surgical Oncology

**Radiation Oncology, Rutgers Cancer Institute of New Jersey

§Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey

Departments of Surgery

Medicine

#Radiology, Rutgers Robert Wood-Johnson University Medical School, New Brunswick, NJ

This research was supported by the following grants to D.R.C.: NCI R01 CA200800, K08 CA172676, Breast Cancer Research Foundation.

D.R.C.: is the founder of Z53 Therapeutics Inc. The remaining authors declare no conflicts of nterest.

Reprints: Darren R. Carpizo, MD, PhD, Rutgers Cancer Institute of New Jersey, 195 Little Albany St. Rm 3040, New Brunswick, NJ 08903. E-mail: carpizdr@cinj.rutgers.edu.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.